Mr. Jim Hutchens reports

IMAGIN MEDICAL ENGAGES TORREY HILLS CAPITAL

Imagin Medical Inc. has engaged San Diego Torrey Hills Capital Inc., an investor relations firm based in Rancho Santa Fe, Calif., to provide market awareness and investor relations services to the company, subject to acceptance by the Canadian Securities Exchange. Cliff Mastricola is the principal of Torrey Hills Capital and will be responsible for all activities related to Imagin.

Torrey Hills Capital is a leading investor and financial public relations firm specializing in small and microcap companies and will increase awareness about Imagin through its established relationships with investment professionals, investment advisers and money managers focused on the microcap market space. This will allow the company to build and maintain an informed investor audience in both the U.S. and Canadian marketplaces.

Imagin has engaged Torrey Hill Capital at a rate of $7,000 (U.S.) per month for an initial term of three months. After the initial term, the agreement will be automatically extended, subject to a 30-day termination notice by either party. Imagin has also agreed to a one-time grant of 100,000 incentive stock options exercisable at a price of 62 cents per share for a period of three years. The options will be subject to the terms of the company's stock option plan and will vest in accordance with the provisions therein and the policies of the Canadian Securities Exchange.

Torrey Hills Capital currently has no direct or indirect interest in the securities of Imagin, or any right or intent to acquire such an interest except pursuant to the exercise of the referenced options.

The appointment of Torrey Hills Capital as an investor relations consultant of Imagin and the granting of the options remain subject to regulatory acceptance of applicable filings with the CSE.

About Imagin Medical Inc.

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue imaging system, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company's initial focus is bladder cancer.

We seek Safe Harbor.